Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631471 | 1.00 | MAPT (0.53) | MAPTADRB2ADRB1CYP2D6PTGS1 | |
| SCHEMBL11848235 | 0.87 | ADRB2 (0.56) | MAPTADRB2ADRB1CYP2D6 | |
| SCHEMBL8348602 | 0.84 | PTGS1 (0.68) | MAPTADRB2ADRB1CYP2D6PTGS1 | |
| SCHEMBL5631180 | 0.84 | PTGS1 (0.68) | MAPTADRB2ADRB1CYP2D6PTGS1 | |
| SCHEMBL5630617 | 0.83 | ADRB2 (0.49) | MAPTADRB2ADRB1PTGS1SLC6A2 | |
| SCHEMBL14572743 | 0.81 | MAPT (0.43) | MAPTADRB2ADRB1CYP2D6PTGS1 | |
| SCHEMBL5630899 | 0.79 | ADRB2 (0.52) | MAPTADRB2ADRB1CYP2D6PTGS1 | |
| SCHEMBL11509194 | 0.76 | ADRB2 (0.57) | ADRB2ADRB1CYP2D6 | |
| SCHEMBL6222984 | 0.75 | CARM1 (0.38) | ADRB2ADRB1CYP2D6 | |
| SCHEMBL11507196 | 0.75 | ADRB2 (0.66) | MAPTADRB2ADRB1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1565472-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ADRB3, PDE3A, PDE3B | MAPT 1575/4885ADRB2 4/4885ADRB1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.